Wetouch Technology Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Wetouch Technology Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $45.14M | Apr 13, 2026 |
| FY2025 | Dec 31, 2024 | $42.28M | Apr 13, 2026 |
| FY2024 | Dec 31, 2023 | $39.71M | Sep 11, 2025 |
| FY2023 | Dec 31, 2022 | $37.92M | Apr 17, 2024 |
| FY2022 | Dec 31, 2021 | $40.79M | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $31.35M | Apr 15, 2022 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $14.20M | Apr 13, 2026 |
| FY2025 | Dec 31, 2024 | $14.94M | Apr 13, 2026 |
| FY2024 | Dec 31, 2023 | $12.04M | Sep 11, 2025 |
| FY2023 | Dec 31, 2022 | $37.92M | Apr 17, 2024 |
| FY2022 | Dec 31, 2021 | $40.69M | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $31.35M | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | $40.00M | Mar 24, 2021 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $14.37M | Apr 13, 2026 |
| FY2025 | Dec 31, 2024 | $13.61M | Apr 13, 2026 |
| FY2024 | Dec 31, 2023 | $17.19M | Sep 11, 2025 |
| FY2023 | Dec 31, 2022 | $14.05M | Apr 17, 2024 |
| FY2022 | Dec 31, 2021 | $18.43M | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $15.61M | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | $19.74M | Mar 24, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.16M | Apr 13, 2026 |
| FY2025 | Dec 31, 2024 | $6.03M | Apr 13, 2026 |
| FY2024 | Dec 31, 2023 | $8.26M | Sep 11, 2025 |
| FY2023 | Dec 31, 2022 | $8.73M | Apr 17, 2024 |
| FY2022 | Dec 31, 2021 | $17.39M | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $8.93M | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | $13.72M | Mar 24, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.97M | Apr 13, 2026 |
| FY2025 | Dec 31, 2024 | $9.32M | Apr 13, 2026 |
| FY2024 | Dec 31, 2023 | $12.65M | Sep 11, 2025 |
| FY2023 | Dec 31, 2022 | $11.41M | Apr 17, 2024 |
| FY2022 | Dec 31, 2021 | $12.62M | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $11.88M | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | $17.00M | Mar 24, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2023 | $84.6K | Sep 11, 2025 |
| FY2023 | Dec 31, 2022 | $85.3K | Apr 17, 2024 |
| FY2022 | Dec 31, 2021 | $89.5K | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $78.0K | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | $136.4K | Mar 24, 2021 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.39M | Apr 13, 2026 |
| FY2025 | Dec 31, 2024 | $1.07M | Apr 13, 2026 |
| FY2024 | Dec 31, 2023 | $12.72M | Sep 11, 2025 |
| FY2023 | Dec 31, 2022 | $8.59M | Apr 17, 2024 |
| FY2022 | Dec 31, 2021 | $14.05M | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $12.96M | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | $10.16M | Mar 24, 2021 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $322.3K | Apr 13, 2026 |
| FY2025 | Dec 31, 2024 | $271.8K | Apr 13, 2026 |
| FY2024 | Dec 31, 2023 | $2.26M | Sep 11, 2025 |
| FY2020 | Dec 31, 2019 | $5.0K | Mar 24, 2021 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $140.64M | Apr 13, 2026 |
| FY2025 | Dec 31, 2024 | $128.02M | Apr 13, 2026 |
| FY2024 | Dec 31, 2023 | $119.64M | Sep 11, 2025 |
| FY2023 | Dec 31, 2022 | $73.11M | Apr 17, 2024 |
| FY2022 | Dec 31, 2021 | $68.68M | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $47.06M | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | $41.74M | Mar 24, 2021 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.24M | Apr 13, 2026 |
| FY2025 | Dec 31, 2024 | $3.43M | Apr 13, 2026 |
| FY2024 | Dec 31, 2023 | $6.72M | Sep 11, 2025 |
| FY2023 | Dec 31, 2022 | $4.27M | Apr 17, 2024 |
| FY2022 | Dec 31, 2021 | $4.37M | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $2.71M | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | $10.08M | Mar 24, 2021 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $137.39M | Apr 13, 2026 |
| FY2025 | Dec 31, 2024 | $124.59M | Apr 13, 2026 |
| FY2025 | Dec 31, 2023 | $112.92M | Apr 13, 2026 |
| FY2024 | Dec 31, 2022 | $68.83M | Sep 11, 2025 |
| FY2023 | Dec 31, 2021 | $64.31M | Apr 17, 2024 |
| FY2022 | Dec 31, 2020 | $44.35M | Apr 17, 2023 |
| FY2021 | Dec 31, 2019 | $31.67M | Apr 15, 2022 |
| FY2020 | Dec 31, 2018 | $18.80M | Mar 24, 2021 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $81.79M | Apr 13, 2026 |
| FY2025 | Dec 31, 2024 | $74.63M | Apr 13, 2026 |
| FY2024 | Dec 31, 2023 | $69.48M | Sep 11, 2025 |
| FY2023 | Dec 31, 2022 | $62.37M | Apr 17, 2024 |
| FY2022 | Dec 31, 2021 | $54.61M | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $39.23M | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | $31.36M | Mar 24, 2021 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $118.36M | Apr 13, 2026 |
| FY2025 | Dec 31, 2024 | $103.76M | Apr 13, 2026 |
| FY2024 | Dec 31, 2023 | $98.04M | Sep 11, 2025 |
| FY2022 | Dec 31, 2022 | $51.25M | Apr 17, 2023 |
| FY2022 | Dec 31, 2021 | $46.16M | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $23.96M | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | $14.28M | Mar 24, 2021 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Apr 13, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Apr 13, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Sep 11, 2025 |
| FY2023 | Dec 31, 2022 | 5 | Apr 17, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | 0 | Mar 24, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Apr 13, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Apr 13, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Sep 11, 2025 |
| FY2023 | Dec 31, 2022 | 4 | Apr 17, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | 0 | Mar 24, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 11.93M | Apr 13, 2026 |
| FY2025 | Dec 31, 2024 | 11.93M | Apr 13, 2026 |
| FY2024 | Dec 31, 2023 | 9.73M | Sep 11, 2025 |
| FY2023 | Dec 31, 2022 | 1.68M | Apr 17, 2024 |
| FY2022 | Dec 31, 2021 | 31.81M | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | 31.50M | Apr 15, 2022 |
| FY2020 | Oct 9, 2020 | 31.40M | Mar 24, 2021 |
| FY2020 | Dec 31, 2019 | 28.00M | Mar 24, 2021 |